3 directorsName after signing inVisible after signing in and 2 others
Owners6 names in the annual accounts
99.9%Hidden nameVisible after signing in and 1 other
Documentsfilings and deeds
30-06-202631 days before the deadline
2025financial year
Turnover from €57.2m to €66.4mResult from €18.3m to €13.6mStaff from 173.5 FTE to 159.1 FTEPower of attorney granted to Name after signing inVisible after signing in04-12Equity from €64.8m to €78.4mInvestments €6.9m
Lower solvency than 80% of companies in pharmaceuticals. Sector median 50.3% · 61 companies.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Hidden signalVisible after signing in
Signal visible after signing inVisible after signing in
Signal hidden, visible after signing inVisible after signing in
Hidden signalVisible after signing in
Signal visible after signing inVisible after signing in
Signal hidden, visible after signing inVisible after signing in
Board and ownership
Hidden nameVisible after signing in
Director
Name after signing inVisible after signing in
Director, Name hiddenVisible after signing in
Hidden nameVisible after signing in
Director, since 15-07-2021
Name after signing inVisible after signing in
Auditor, Name hiddenVisible after signing in
Hidden nameVisible after signing in 99.9%score XXVisible after signing inequity €212.9m (2025) · annual accounts 2025 of Name hiddenVisible after signing in
Hidden nameVisible after signing in consolidatesannual accounts 2025
Shares in 5 companies, including Name hiddenVisible after signing in and Hidden nameVisible after signing in
3 directors reappointed, 1 statutory auditor reappointedName after signing inVisible after signing in, Name hiddenVisible after signing in, Hidden nameVisible after signing in and Name after signing inVisible after signing in (statutory auditor) · General meeting of 03-07-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0428242033
Name hiddenVisible after signing in resigns as director
General meeting of 31-03-2026 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
Grey: the largest companies of the sector (pharmaceuticals (NACE 21)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as PHYSIOL: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €43m and €262m, founded between 1958 and 1998.